TipRanks
Advertisement
Advertisement

DE:5VA Stock Latest News

Mizuho biotech analysts hold an analyst/industry conference call
The FlyMizuho biotech analysts hold an analyst/industry conference call
2d ago
BBIO
BIIB
Vaxcyte price target lowered to $130 from $133 at BofA
PremiumThe Fly
Vaxcyte price target lowered to $130 from $133 at BofA
6d ago
PCVX
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
PremiumCompany Announcements
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
1M ago
8K
PCVX
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
PremiumThe Fly
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
1M ago
PFE
PCVX
Vaxcyte narrows previously communicated VAX-31 guidance
PremiumThe Fly
Vaxcyte narrows previously communicated VAX-31 guidance
1M ago
PCVX
Analyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts
PremiumRatingsAnalyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts
2M ago
PCVX
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
Premium
The Fly
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
2M ago
PCVX
Vaxcyte Announces Board Transition and New Director Appointment
Premium
Company Announcements
Vaxcyte Announces Board Transition and New Director Appointment
3M ago
8K
PCVX
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
PremiumCompany Announcements
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
4M ago
8K
PCVX
Vaxcyte doses first participant in VAX-A1 study
PremiumThe Fly
Vaxcyte doses first participant in VAX-A1 study
4M ago
PCVX
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
PremiumThe Fly
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
5M ago
PCVX
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
PremiumThe Fly
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
6M ago
PCVX
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
PremiumThe FlyVaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
7M ago
PCVX
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
Premium
Company Announcements
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
7M ago
PCVX
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
Premium
Company Announcements
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
7M ago
PCVX
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
PremiumRatings
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
7M ago
PCVX
Vaxcyte price target raised to $89 from $85 at BTIG
PremiumThe Fly
Vaxcyte price target raised to $89 from $85 at BTIG
7M ago
PCVX
Vaxcyte price target lowered to $133 from $134 at BofA
PremiumThe Fly
Vaxcyte price target lowered to $133 from $134 at BofA
7M ago
PCVX
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
PremiumThe Fly
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
7M ago
PCVX
Vaxcyte price target raised to $75 from $50 at TD Cowen
PremiumThe FlyVaxcyte price target raised to $75 from $50 at TD Cowen
7M ago
PCVX
Vaxcyte Launches New $500 Million ATM Equity Program
Premium
Company Announcements
Vaxcyte Launches New $500 Million ATM Equity Program
7M ago
8K
PCVX
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
Premium
The Fly
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
7M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >